ClinicalTrials.gg
RecruitingNCT07225868Updated Nov 10, 2025

Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?

An interventional study of Conscientiousness Coaching Before Cognitive Rehabilitation and Sham Intervention Before Cognitive Rehabilitation in Multiple Sclerosis, sponsored by Universiteit Leiden. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Universiteit Leiden · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 258 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Planned enrollment
215th of 879
126 · median 50
Started
2025
with 56 others
No phase
381 of 1,192
69 open now
Primary completion
2028-12
later than 192 of 255 live
Registered
1,138th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 215th largest by planned enrollment of the 879 interventional ones that give a count, is one of 57 that started in 2025, is one of 381 with no phase, reaches primary completion later than 192 of the 255 other live ones, and was the 1,138th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous research on cognitive rehabilitation has shown that regular training focused on memory and concentration can have positive effects on cognitive functioning, including processing speed, memory, and executive functions that support daily activities. Moreover, fMRI studies (brain scans that measure brain activity) have revealed changes in brain activation following cognitive rehabilitation.

Recently, the idea has emerged that a more personalized approach could improve treatment outcomes. Specifically, researchers have identified a link between personality traits and cognitive functioning. Since every individual is different, current cognitive rehabilitation programs often fail to take these personal differences into account.

In this project, the investigators aim to enhance the effectiveness of cognitive rehabilitation by focusing more closely on individual characteristics through an app-based training program. Participants will complete a 12-week app training prior to a 6-week cognitive rehabilitation program. The first app focuses on mindset training, supported by a coach. Afterwards, all participants will use a second app designed to train processing speed and memory. In addition to cognitive functioning, the investigators will also examine psychological, (neuro)biological, and social changes using questionnaires and fMRI. This research may provide valuable insights into how cognitive functioning and quality of life in people with MS can be improved.

This study is funded by the National MS Fund and is a collaboration between several institutions: the Department of Health, Medical and Neuropsychology at Leiden University (The Netherlands), the University at Buffalo (USA), and Reha Rheinfelden (Switzerland).

Read the detailed description

Rationale: Cognitive impairment displays a common and impacting symptom in people with multiple sclerosis (PwMS). It has been shown that PwMS benefit from cognitive rehabilitation (CR), but group-effects are mild-to-moderate and effect sizes vary between patients, highlighting the need for including individual factors in investigating CR. It has been shown that PwMS with high conscientiousness, a personality trait that is associated with being well-organised, schema driven, achievement-striving and goal-directed show higher improvement on cognitive functions. Very recent data shows that it is possible to enhance conscientiousness in PwMS and that this increase led to more goal-directed behaviour, decreased depressive symptoms and improvements in QoL.

Objective: To investigate if conscientiousness coaching (C-Coach) before CR will enhance the treatment effects of CR, in which treatment effect is operationalised as improvement from a full comprehensive perspective of well-being of PwMS Study design: This experimental multicentre study in the Netherlands, United States and Switzerland follows a longitudinal, parallel group, controlled design with three assessment sessions including behavioural testing for both study groups and brain imaging in a subsample. Additionally, both groups will undergo either 12-weeks of C-Coach or sham training before six weeks of CR.

Study population: The study population consists of 126 PwMS aged between 18 and 65 years, of which group 1 (N= 63) will undergo C-Coach before CR and group 2 (N= 63) will undergo a sham intervention before CR.

Intervention: All interventions will be performed on mobile devices and can thus be done at home. Group 1 will undergo 12 weeks of C-Coach, which consists of a pre-session and two booster sessions with a coach to explain goals, values and the training application as well as the self-use of the smartphone application C-Coach between sessions to track goals and values. Group 2 will undergo 12 weeks of sham intervention, consisting of a pre-session and two booster sessions with a coach to discuss early life memories and the self-use of the smartphone application Daily Notes to journal about early life memories. Both groups will undergo CR after C-Coach or sham intervention, where they are asked to perform two 60-minutes training sessions per week for the duration of 6 weeks using the CR training application BrainHQ.

Main study parameters/endpoints: Main endpoint will be subjective and objective cognitive changes between baseline and post-intervention on processing speed task and improved cognitive functioning in daily life in PwMS in the intervention group compared to PwMS in the control group. As secondary endpoints, changes between baseline and post-intervention on goal attainment, meaning of life, fatigue, depression, anxiety, cognitive functioning, functional brain networks and social support in PwMS in the intervention group (C-Coach prior to CR) compared to PwMS in the control group (sham intervention prior to CR) will be studied.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risk of proposed interventions and procedures including MRI scan is negligible, as both can be seen as safe and non-invasive. All participants in the subsample undergoing MRI scans will undergo a detailed screening for MRI contradictions to exclude any risks. The confined space inside the MRI device for the duration of 25 minutes of the scan as well as the time investment of the participant for travel to study location and participation involves some burden for the participants. This study will offer valuable insights in the development of effective cognitive rehabilitation strategies, which will in turn positively impact patients' QoL and their ability to participate in society as they see fit.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • Conscientiousness
  • Cognitive Rehabilitation
  • Brain Imaging
  • Quality of Life
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed relapsing remitting or secondary progressive MS diagnosis according to the McDonald 2017 criteria
  • Expanded Disability Status Scale (EDSS) score \< 7
  • Relapse free period ≥ 3 months
  • Unchanged disease modifying therapy for ≥ 2 months at time of inclusion
  • Age 18-65 years
  • Language Dutch, English or German for each centre respectively

Exclusion criteria

Exclusion Criteria:

  • High conscientiousness, measured with a T score 65 or higher on the BFI-2 subscale for conscientiousness
  • Current or prior brain trauma or neurological condition (other than MS)
  • Psychiatric disorder that heavily impacts cognitive and/or daily functioning
  • Medication intake and/or substance abuse that has an influence on cognitive functioning
  • For Dutch subsample undergoing MRI: Contradiction for MRI
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Conscientiousness Coaching

    Behavioral: Conscientiousness Coaching Before Cognitive Rehabilitation

  • Sham comparator
    Sham Intervention

    Behavioral: Sham Intervention Before Cognitive Rehabilitation

Interventions

  • BehavioralConscientiousness Coaching Before Cognitive Rehabilitation

    In this arm, participants complete the conscientiousness coaching before the cognitive rehabilitation. All participants (both arms) will receive 6 weeks of cognitive rehabilitation using BrainHQ (2 times per week, 1 hour each).

  • BehavioralSham Intervention Before Cognitive Rehabilitation

    In this arm, participants complete the sham intervention before the cognitive rehabilitation. All participants (both arms) will receive 6 weeks of cognitive rehabilitation using BrainHQ (2 times per week, 1 hour each).

06

What researchers measure

Primary outcomes

  1. Objective cognitive changes between baseline and post-intervention

    Objective cognitive changes between baseline and post intervention will be assessed using the Symbol Digit Modalities Test assessing information processing speed.

    Time frame: Between baseline and week 18.

  2. Subjective cognitive changes between baseline and post-intervention

    Subjective cognitive changes between baseline and post intervention will be assessed using the Multiple Sclerosis Instrumental Activities of Daily Living Questionnaire.

    Time frame: Between baseline and week 18.

Secondary outcomes

  1. Changes between baseline and week 18 on meaning of life in the intervention compared to the sham intervention group.

    Changes on the Meaning of Life Questionnaire comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  2. Changes between baseline and week 18 on fatigue in the intervention compared to the sham intervention group.

    Changes on the Checklist of Individual Strength comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  3. Changes between baseline and week 18 on quality of life in the intervention compared to the sham intervention group.

    Changes on the 36-Item Short Form Survey comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  4. Changes between baseline and week 18 on psychological outcomes in the intervention compared to the sham intervention group.

    Changes on the Hospital Anxiety and Depression Scale comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  5. Changes between week 12 and week 18 on goal attainment in the intervention compared to the sham intervention group.

    Changes on the Goal Attainment Scale comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between week 12 and week 18.

  6. Changes between baseline and week 18 on multiple sclerosis specific cognitive functioning in the intervention compared to the sham intervention group.

    Changes on the Brief International Cognitive Assessment for Multiple Sclerosis comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  7. Changes between baseline and week 18 on cognitive flexibility in the intervention compared to the sham intervention group.

    Changes on the Trail Making Test A and B comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  8. Changes between baseline and week 18 on verbal fluency in the intervention compared to the sham intervention group.

    Changes on the Controlled Oral Word Association Test comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  9. Changes between baseline and week 18 executive functions in the intervention compared to the sham intervention group.

    Changes on the Stroop Test comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  10. Changes between baseline and week 18 on functional networks in the intervention compared to the sham intervention group.

    Changes on functional networks measured with resting state functional magnetic resonance imaging comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  11. Changes between baseline and week 18 on structural networks in the intervention compared to the sham intervention group.

    Changes on Structural networks measured with Diffusion Tensor Imaging comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

  12. Changes between baseline and week 18 on social outcomes in the intervention compared to the sham intervention group.

    Changes on the Medical Outcomes Study Social Support Survey comparing the intervention (C-Coach prior to CR) group with the sham intervention group.

    Time frame: Between baseline and week 18.

Other outcomes

  1. Effect of personality

    The effect of baseline trait conscientiousness, neuroticism and personality measured with the Big Five Inventory 2 on all outcomes.

    Time frame: Between baseline and week 18.

  2. Effect of demographics

    The effect of baseline demographic variables, namely age, sex, nationality, and education will be studied on the described outcomes.

    Time frame: Between baseline and week 18.

  3. Effect of C-Coach

    The main and secondary outcomes will be measured at week 12 after C-Coach or sham intervention and before the start of CR in order to replicate previous preliminary findings.

    Time frame: Between baseline and week 12.

  4. Feedback on C-Coach or sham intervention

    Participants' responses to a Feedback Questionnaire will be examined at week 18, which includes specific questions about the effectiveness and the experience of the intervention.

    Time frame: At week 18.

07

Study locations

1 of 3 sites recruiting
  • Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo
    Buffalo, New York 14203, United States
    Not yet recruiting
    • Ralph HB Benedict, Prof · Contactbenedict@buffalo.edu · 716-323-0556
    • Ralph HB Benedict, Prof · Principal investigator
  • Health, Medical and Neuropsychology, Institute of Psychology, Faculty of Behvavioural and Social Siences, Leiden University
    Leiden, 2333AK, Netherlands
    Recruiting
    • Charlotte C Rouzée, MSc · Contactc.c.rouzee@fsw.leidenuniv.nl · 062 831 93 32
    • Hanneke E Hulst, Prof · Principal investigator
    • Marit FL Ruitenberg, PhD · Principal investigator
    • Charlotte C Rouzee, MSc · Sub investigator
  • Research Department, Reha Rheinfelden
    Rheinfelden, 4310, Switzerland
    Not yet recruiting
    • Priska Zuber, PhD · Contactp.zuber@reha-rhf.ch · 061 836 53 80
    • Corina Schuster-Amft, PD PhD · ContactC.Schuster@reha-rhf.ch · 061 836 53 81
    • Priska Zuber, PhD · Principal investigator
    • Corina Schuster-Amft, PD PhD · Principal investigator
    • Katrin Parmar, Dr. med · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Dec 2028, 37 months later.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 37 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2025
First posted
Nov 10, 2025
StartEst.
Nov 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225868
Lead sponsor
Universiteit Leiden
Collaborators
Reha Rheinfelden, University at Buffalo
Responsible party
Marit Ruitenberg (PhD, Universiteit Leiden) — Principal investigator
First posted
Nov 10, 2025
Start date
Nov 1, 2025 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 10, 2025

Study contacts

Charlotte C Rouzee, MSc
Contact
c.c.rouzee@fsw.leidenuniv.nl
062 831 93 32 ext. +31
Marit FL Ruitenberg, PhD
Contact
m.f.l.ruitenberg@fsw.leidenuniv.nl
071 527 2727 ext. +31
Hanneke E Hulst, Prof
principal investigator · Leiden University
Priska Zuber, PhD
principal investigator · Reha Rheinfelden
Ralph HB Benedict, Prof
principal investigator · Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo
Marit FL Ruitenberg, PhD
principal investigator · Leiden University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion